Occuity plans to continue to hire the greatest minds in their disciplines, bringing jobs to Reading and the Thames Valley, after growing from a staff of 10 in December 2020 to over 35 presently.
FREMONT, CA: Occuity, a medical technology start-up established in the Thames Valley, reaches its 1.8 million pounds funding goal just 24 hours after launching on Seedrs, the premier crowdfunding site. The company now plans to ‘overfund’ while the round is still available, allowing them to accelerate the development of their unique optical devices.
CEO and Co-founder Dr. Dan Daly comments: “We are delighted with the level of interest we have received during this finance round and are thrilled that we are now overfunding. To date we have now raised over 2 million pounds which will allow us to accelerate the development of our new optical screening and monitoring devices that aim to detect the early signs of chronic health conditions by scanning the human eye.”
Occuity, which was founded in 2019, has invented and patented a contactless optical technique that allows it to take exact measurements from the eye. The business’s mission is to use the eye as a window into the health of the body and to use their non-invasive, non-contact handheld technology to bring a variety of new medical devices to market; including ophthalmic examinations, pre-diabetes screening, diabetes management, and, in the long run, early detection of Alzheimer’s condition.
“Diabetes is a very personal issue and of course, once you have it, it is likely with you for the rest of your life. As our long-term products will be personal use meters for people with diabetes, we wanted to give our community of 8,000 people with diabetes the opportunity to become full shareholders in our business and to join us on this journey to try to improve their lives,” Dr. Daly said:
Occuity intends to use the funds raised in this round to expand its team. The company plans to continue to hire the greatest minds in their disciplines, bringing jobs to Reading and the Thames Valley, after growing from a staff of 10 in December 2020 to over 35 presently. By 2023, the company estimates to employ 100 people.
The following items are included in Occuity’s new medical device roll-out plan:
The PM1 Pachymeter, Occuity’s first gadget, is aimed at the optometry sector and assesses corneal thickness with micrometer precision. Clinical testing will begin soon, and it is expected to be licensed for use in the EU by early 2022.
In 2024, the business hopes to offer a pre-diabetic screening gadget at pharmacies and opticians, allowing for mass testing for the early indicators of Type 2 diabetes.
It plans to release a personal non-invasive optical glucose monitor in 2025, allowing people with diabetes to check their blood sugar levels without having to extract blood.
Occuity assures that its research and development will help bring routine screening equipment to market that can detect early indicators of Alzheimer’s disease by detecting biomarkers deposited in the eye.